A
Anthony W. Tolcher
Researcher at Texas Oncology
Publications - 501
Citations - 20529
Anthony W. Tolcher is an academic researcher from Texas Oncology. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 65, co-authored 443 publications receiving 18503 citations. Previous affiliations of Anthony W. Tolcher include University of Texas at Austin & Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis,Jonathan E. Zuckerman,Chung Hang Jonathan Choi,David Seligson,Anthony W. Tolcher,Christopher A. Alabi,Christopher A. Alabi,Yun Yen,Jeremy D. Heidel,Antoni Ribas +9 more
TL;DR: Evidence is provided of inducing an RNAi mechanism of action in a human from the delivered siRNA and the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for anRNAi mechanism from a patient who received the highest dose of the nanoparticles.
Journal ArticleDOI
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Manuel Hidalgo,Lillian L. Siu,John Nemunaitis,Jinee Rizzo,Lisa A. Hammond,Chris H. Takimoto,S. Gail Eckhardt,Anthony W. Tolcher,Carolyn D. Britten,Louis Denis,Karen J. Ferrante,Daniel D. Von Hoff,Sandra L Silberman,Eric K. Rowinsky +13 more
TL;DR: The recommended dose for disease-directed studies of OSI-774 administered orally on a daily, continuous, uninterrupted schedule is 150 mg/d, and several patients with epidermoid malignancies demonstrated either antitumor activity or relatively long periods of stable disease.
Journal ArticleDOI
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik,S. Peter Kang,Drew W. Rasco,Kyriakos P. Papadopoulos,Jeroen Elassaiss-Schaap,Muralidhar Beeram,Ronald Drengler,Cong Chen,Lon Smith,Guillermo Espino,Kevin Gergich,Liliana Delgado,Adil Daud,Jill A. Lindia,Xiaoyun Nicole Li,Robert H. Pierce,Jennifer H. Yearley,Dianna Wu,Omar F Laterza,Manfred Lehnert,Robert Iannone,Anthony W. Tolcher +21 more
TL;DR: Pembrolizumab was well tolerated and associated with durable antitumor activity in multiple solid tumors, and Mechanism-based translational models with a focus on intratumor exposure prediction suggested robust clinical activity would be observed at doses ≥2 mg/kg every 3 weeks.
Journal ArticleDOI
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik,Lee S. Rosen,Sara M. Tolaney,Anthony W. Tolcher,Jonathan W. Goldman,Leena Gandhi,Kyriakos P. Papadopoulos,Muralidhar Beeram,Drew W. Rasco,John Hilton,Aejaz Nasir,Richard P. Beckmann,Andrew E. Schade,Angie D. Fulford,Tuan S. Nguyen,Ricardo Martinez,Palaniappan Kulanthaivel,Lily Q. Li,Martin Frenzel,Damien M. Cronier,Edward M. Chan,Keith T. Flaherty,Patrick Y. Wen,Geoffrey I. Shapiro +23 more
TL;DR: Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition, and this first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors.
Journal ArticleDOI
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap,Li Yan,Amita Patnaik,Ivy Fearen,David Olmos,Kyriakos P. Papadopoulos,Richard D. Baird,Liliana Delgado,Adekemi Taylor,Lisa Lupinacci,Ruth Riisnaes,Lorna Pope,Simon P. Heaton,George Thomas,Michelle D. Garrett,Daniel M. Sullivan,Johann S. de Bono,Anthony W. Tolcher +17 more
TL;DR: MK-2206 was well tolerated, with evidence of AKT signaling blockade, and Rational combination trials are ongoing to maximize clinical benefit with this therapeutic strategy.